CVRx Sets IPO at 6.25 Million Shares; Sees Pricing at $15-$17 Each
June 23 2021 - 7:04AM
Dow Jones News
By Colin Kellaher
CVRx Inc. on Wednesday said it plans to sell 6.25 million shares
at between $15 and $17 each in its initial public offering.
At the $16 midpoint of the expected price range, the Minneapolis
medical-device company backed by Johnson & Johnson said it
expects net proceeds of about $91.5 million, or around $105.5
million if the underwriters exercise an option to buy an additional
937,500 shares.
CVRx said it expects to use the bulk of the proceeds to fund the
expansion of its direct sales force and commercial organization
related to its Barostim NEO device in the U.S.
Johnson & Johnson's strategic-venture arm currently holds a
nearly 32% stake in CVRx and will still own more than 20% after the
IPO.
In a filing with the U.S. Securities and Exchange Commission,
CVRx said it would have about 19.5 million shares outstanding after
the IPO, assuming exercise of the overallotment option, for a
market capitalization of roughly $312 million at the $16-a-share
pricing midpoint.
CVRx said it expects its shares will trade on the Nasdaq Global
Market under the symbol CVRX.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
June 23, 2021 06:55 ET (10:55 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Sep 2023 to Sep 2024